Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Leukemia, B-cell

The First Affiliated Hospital with Nanjing Medical UniversityCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Leukemia, B-cell cohort.

Asset / SponsorPhaseRating
Fludarabine
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Busulphan
Dartmouth-Hitchcock Medical Center
Phase 4BB
Pirtobrutinib
Loxo Oncology, Inc.
Phase 3BB
DEXAMETHASONE
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →